# Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)

> **NCT05036005** · PHASE4 · UNKNOWN · sponsor: **Institut fuer Frauengesundheit** · enrollment: 108 (estimated)

## Conditions studied

- Breast Cancer
- Breast Neoplasms
- Breast Cancer Female
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Ontruzant
- **DRUG:** Chemotherapy
- **DRUG:** Pertuzumab

## Key facts

- **NCT ID:** NCT05036005
- **Lead sponsor:** Institut fuer Frauengesundheit
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-11
- **Primary completion:** 2023-04
- **Final completion:** 2023-07
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05036005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05036005, "Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05036005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*